Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Petosemtamab secures a buyout for Merus
Genmab acquires the Dutch biotech for $8bn.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
